The transgenic mice most commonly employed in AD research are based on the up-regulation of the APP, including the APPTg2576, APPV717F and CRND8, transgenic lines, which usually show amyloid deposition in hippocampus and cortex and memory deficits, but not neuronal loss. The gene discussed is APP; the disease is Alzheimer disease.